Improving the detection and management of AF in the North West Coast

Framework service specification for anticoagulation management of people with atrial fibrillation

This document is a framework service specification for the delivery of anticoagulation services for people with atrial fibrillation (AF). The specification was developed by Anticoagulation UK in close collaboration with experts in anticoagulation from across primary, community and secondary care. The standards within this framework reflect best practice for services to adhere to, both during and beyond the COVID-19 pandemic. This project has been fully funded by Bayer plc. The content is independent of and not influenced by Bayer plc who checked the final document for technical accuracy only.

Independent evaluation of the AHSN Network mobile ECG roll-out programme

The national roll out of mobile ECG devices by Academic Health Science Networks (AHSNs) was born out of a system-wide procurement initiative to promote the uptake of a digital technology (mobile ECG). This was a novel approach to facilitate innovation adoption which prompted the AHSN Network to commission an independent evaluation of the roll out, at AHSN level, to understand its effectiveness, and in particular what can be learned about: the environments in which the devices are most effective, what characterises an effective implementation package, the impact on the market place, patients (through AF detection) and providers; and the health economic aspects of this type of programme.

Adapting stroke services during the COVID-19 pandemic: an implementation

Getting It Right First Time (GIRFT) programme

Guidance for the safe switching of warfarin to direct oral anticoagulants (DOACs) for patients with non-valvular AF and venous thromboembolism (DVT / PE) during the coronavirus pandemic

Clinical guide for the management of anticoagulant services during the coronavirus pandemic

Anticoagulant services may not seem to be in the frontline with coronavirus but we do have a key role in continuing to keep patients on anticoagulants as safe as possible; this must be planned. In response to pressures on the NHS, the way we deliver anticoagulants may need to change. We should seek the best local solutions to continue the safe management of patients on anticoagulation while protecting resources for the response to coronavirus

Public Health England CVD Ambitions

A new coalition led by Public Health England (PHE) and NHS England has announced the first ever national ambitions to improve the detection and treatment of atrial fibrillation, high blood pressure and high cholesterol (A-B-C) – the major causes of cardiovascular disease (CVD).

Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system)

Atrial Fibrillation as an Independent Risk Factor for Stroke: The Framingham Study

The impact of nonrheumatic atrial fibrillation, hypertension, coronary heart disease, and cardiac failure on stroke incidence was examined in 5,070 participants in the Framingham Study after 34 years of follow-up.

Improving the detection and management of AF in the North West Coast

Download

More Additional Reading